SubsidieMeestersAlkaBurst2.0 – A game changing bioreactor for sustainable production of active pharmaceutical ingredients in a consistent, traceable and low cost approach
Alkion is developing a sustainable biorefinery using its AlkaBurst2.0 technology to produce high-quality APIs locally, aiming for significant cost savings and revenue growth by 2028.
Projectdetails
Introduction
Alkion, a revolutionary biotech company, is developing a breakthrough biorefinery to produce top quality active pharmaceutical ingredients (API) and extracts in plants in a sustainable and cost-effective way.
Technology Overview
Our core technology combines our disruptive patented automated bioreactor - AlkaBurst2.0 - with unique know-how on gene expression methods, culture media, and extraction. Our process offers high productivity and a low carbon footprint.
Industry Challenges
The pharma industry is carbon intensive with recurring problems of quality and safety. Moreover, many critical APIs are outsourced to Asia to cut costs.
Solution
AlkaBurst2.0 allows a local standardized production of safe and clean APIs in its automated process, saving:
- 75% time
- 80% space
- 95% electricity
- 98% water
Market Validation
We first validated the production for Covid-19 natural vaccine adjuvants QS21/7, cannabinoids, and certain recombinant proteins for the urgent market demand.
Funding and Revenue Expectations
We need €7.5M to build and validate our pilot and expect to generate €125M in revenue by 2028, creating 105 jobs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 3.586.937 |
Tijdlijn
| Startdatum | 1-11-2022 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ALKION BIOINNOVATIONSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes. | EIC Accelerator | € 2.306.500 | 2024 | Details |
Autonomous robotics and digital TWIN to improve water network performancesThe project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model. | EIC Accelerator | € 2.478.210 | 2024 | Details |
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming systemToopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability. | EIC Accelerator | € 2.396.457 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
"The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents"""
NIMBLE Diagnostics is developing a microwave-based device for non-invasive stent monitoring, aiming to shift from reactive to proactive care and improve patient outcomes.
Autonomous robotics and digital TWIN to improve water network performances
The project develops a robotic inspection system for water utilities, enabling autonomous pipeline assessments to enhance water quality and sustainability through a subscription-based RaaS model.
Toopi Regen: Unleash the power of urine to finally scale a real closed loop and regenerative farming system
Toopi Organics aims to revolutionize agriculture by up-cycling human urine into sustainable biostimulants, reducing reliance on mineral fertilizers while enhancing soil health and farmer profitability.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Continuous Digitalized Processes for Producing BiopharmaceuticalsDeveloping a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine. | ERC ADG | € 2.500.000 | 2023 | Details |
Development & demonstration of low environmental impact innovation and optimization practices in pharma productionLIFE-GREENAPI aims to revolutionize API production in Europe by implementing flow-chemistry to enhance sustainability, reduce environmental impact, and support the pharmaceutical sector's decarbonization efforts. | LIFE SAP | € 1.516.536 | 2023 | Details |
Bioraffinage van eiwitstrengen uit biomassa tbv. Pharma en (bulk)chemieHet project richt zich op het ontwikkelen van processen voor het winnen van eiwitten uit biomassa, gericht op duurzame toepassingen in de chemie en farmacie, ter ondersteuning van de groeiende vraag naar eiwitten. | MIT Haalbaarheid | € 20.000 | 2021 | Details |
Microbiële cel fabriekjes voor de productie van OxytetracyclineEV Biotech ontwikkelt microbiële cel fabriekjes voor duurzame productie van het antibioticum Oxytetracycline, waarbij digitale modellering kosten en tijd reduceert en milieueffecten minimaliseert. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
Continuous Digitalized Processes for Producing Biopharmaceuticals
Developing a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine.
Development & demonstration of low environmental impact innovation and optimization practices in pharma production
LIFE-GREENAPI aims to revolutionize API production in Europe by implementing flow-chemistry to enhance sustainability, reduce environmental impact, and support the pharmaceutical sector's decarbonization efforts.
Bioraffinage van eiwitstrengen uit biomassa tbv. Pharma en (bulk)chemie
Het project richt zich op het ontwikkelen van processen voor het winnen van eiwitten uit biomassa, gericht op duurzame toepassingen in de chemie en farmacie, ter ondersteuning van de groeiende vraag naar eiwitten.
Microbiële cel fabriekjes voor de productie van Oxytetracycline
EV Biotech ontwikkelt microbiële cel fabriekjes voor duurzame productie van het antibioticum Oxytetracycline, waarbij digitale modellering kosten en tijd reduceert en milieueffecten minimaliseert.